Anti-Human CD44 (Clone E1/2) – DyLight® 755

Anti-Human CD44 (Clone E1/2) – DyLight® 755

Product No.: C1802

[product_table name="All Top" skus="C1802"]

- -
- -
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Hermes, Pgp-1, H-CAM, HUTCH-1, ECMR III, gp85, Ly-24

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Host Species
Purified Recombinant Human CD44 (>98%)
Product Concentration
0.1 mg/ml
This DyLight<sup>®</sup> 755 conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 755 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this E1/2 antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone E1/2 recognizes human CD44.
The CD44 antigen is the cellular receptor for hyaluronic acid. Anti-Human CD44 may be used to study cellular homing and adhesion. This antibody may also be used in studies of T-lymphocytCD44 is an 80-95 kD glycoprotein that plays a role in various cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis. CD44 interacts with osteopontin, collagens, and matrix metalloproteinases (MMPs) and is a receptor for hyaluronic acid. Transcripts for this gene go through intricate alternative splicing that result in a variety of functionally distinct isoforms, including those which may be related to tumor metastasis. These splice variants of CD44 function as receptors under hemodynamic flow conditions that are significant to the development of cancer metastasis. Hence, it is thought that anti-CD44 tumor-specific mAbs may have therapeutic potential. This therapeutic potential of anti-CD44 mAbs is evident in some animal experiments demonstrating a reduction in malignant activities of various neoplasms when CD44 was targeted by a combination of mAbs, antisense oligonucleotides, and CD44-soluble proteins. It has been reported that high levels of CD44 on leukemic cells fuel leukemia production. Notably, various cancer studies show conflicting results pertaining to level of CD44 expression and its correlation with disease prognosis. Before anti-CD44 therapy can be applied to human cancers, it is essential to resolve this inconsistency. e activation.
Antigen Distribution
CD44 is expressed on all leukocytes, endothelial cells, hepatocytes, and mesenchymal cells in addition to B-cells, monocytes, macrophages and certain subsets of thymocytes and peripheral T-cells. Mice with the Ly-24.1 allotype have high densities of CD44+ T-cells.

Antigen Details

Hyaluronan, MIP-1β, fibronectin, collagen
NCBI Gene Bank ID
Research Area
Cell Adhesion
Cell Biology
Stem Cell

References & Citations

1. Isacke, M.C. et al. (1986) Immunogenetics 23:326
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.